Article
Hematology
Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, Stefan Schmitl, Hans-Juergen Wester, Alexander Haug
Summary: This study aimed to evaluate the potential alternative of CXCR4 tracer [Ga-68]Pentixa-for combined with positron emission tomography (PET) for the assessment of residual gastric MALT lymphoma after Helicobacter pylori eradication. The results showed high accuracy, sensitivity, specificity, and positive predictive value for this method.
Article
Oncology
Hidehiko Takigawa, Ryo Yuge, Satoshi Masaki, Rina Otani, Hiroki Kadota, Toshikatsu Naito, Ryohei Hayashi, Yuji Urabe, Shiro Oka, Shinji Tanaka, Kazuaki Chayama, Yasuhiko Kitadai
Summary: For gastric MALT lymphoma cases that are Helicobacter pylori-negative and API2-MALT1-negative, a high rate of non-Helicobacter pylori Helicobacter infections was observed, which may have contributed to the success of eradication therapy. Therefore, eradication therapy is recommended as a first-line treatment for non-Helicobacter pylori Helicobacter-positive gastric MALT lymphoma.
Article
Oncology
Barbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, Fangtian Wu, Jehan Dupuis, Caroline Barau, Luca Arcaini, Marco Paulli, Marco Lucioni, Arturo Bonometti, Antonio Salar, Concepcion Fernandez-Rodriguez, Miguel A. Piris, Francesco Cucco, Rachel Dobson, Yan Li, Zi Chen, Cyrielle Robe, Ingrid Simonitsch-Klupp, Andrew Wotherspoon, Markus Raderer, Ming Qing Du
Summary: The study reveals that H. pylori negative gastric MALT lymphoma is characterized by frequent genetic changes in the NF-kappa B signaling pathways. However, these genetic changes do not show significant correlation with clinicopathological parameters, and patients treated with systemic therapy have significantly better progression-free survival compared to those treated with antibiotics.
Article
Biochemistry & Molecular Biology
Chiara Della Bella, Maria Felicia Soluri, Simone Puccio, Marisa Benagiano, Alessia Grassi, Jacopo Bitetti, Fabio Cianchi, Daniele Sblattero, Clelia Peano, Mario Milco D'Elios
Summary: The study showed that CagY drives both B cell proliferation and T cell activation in gastric MALT lymphomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Fabian Fellipe Bueno Lemos, Marcel Silva Luz, Samuel Luca Rocha Pinheiro, Kadima Nayara Teixeira, Fabricio Freire de Melo
Summary: Gastric mucosa-associated lymphoid tissue lymphoma (GML) is a low-grade B-cell neoplasia commonly associated with chronic gastritis induced by Helicobacter pylori (H. pylori) infection. However, a subset of GML patients are H. pylori-negative. Despite previous beliefs, it has been found that a considerable proportion of H. pylori-negative GML patients show complete remission after bacterial eradication therapy. The mechanisms underlying this treatment responsiveness are not fully understood, and further research is needed to establish the causal relationship between non-H. pylori gastric helicobacters (NHPHs) and GML.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Computer Science, Artificial Intelligence
Xia Pan, Cheng Fang, Yan Chen
Summary: This study found that gastric mucosal tissue lymphoma is one of the most common types of stomach tissue-related gonorrhea, and most lymphomas are related to Helicobacter pylori infection. The article describes the signs and treatments for 12 patients with lymphoma.
Review
Oncology
Sung-Hsin Kuo, Kun-Huei Yeh, Chung-Wu Lin, Jyh-Ming Liou, Ming-Shiang Wu, Li-Tzong Chen, Ann-Lii Cheng
Summary: The prevalence of HP-negative gastric MALT lymphoma has increased, while HP-positive gastric MALT lymphoma has decreased. Some case studies have shown that a first-line HP eradication therapy (HPE)-like regimen can result in complete remission for some patients with localized HP-negative gastric MALT lymphoma. Previous sporadic reports have also indicated that some patients with extragastric MALT lymphoma can respond to antibiotic treatment.
Article
Pathology
Sean X. Gu, Alexa J. Siddon, Scott F. Huntington, Dhanpat Jain
Summary: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is commonly associated with Helicobacter pylori (HP) infection, but the incidence of HP-negative MALT lymphoma is increasing. Some HP-negative patients have chronic gastritis, while others do not. HP-negative patients without gastritis are more likely to have a mass lesion. Treatment for HP-negative patients varies, but the prognosis is excellent.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Medicine, General & Internal
Takahide Tanaka, Yuichi Matsuno, Takehiro Torisu, Hiroki Shibata, Atsushi Hirano, Junji Umeno, Keisuke Kawasaki, Shin Fujioka, Yuta Fuyuno, Tomohiko Moriyama, Motohiro Esaki, Takanari Kitazono
Summary: The study found that there are significant changes in the gastric mucosal microbial compositions of patients with H. pylori-negative MALT lymphoma, suggesting that altered microbiota might be involved in the pathogenesis of the disease.
Article
Oncology
Michael P. MacManus, Daniel Roos, Peter O'Brien, Anne Capp, Andrew Wirth, Richard Tsang, Mathias Bressel, Stephen Lade, John F. Seymour
Summary: The study showed that radiotherapy has the potential to be a curative treatment with low toxicity for localized non-gastric marginal zone lymphoma. 60% of patients were found to have autoimmunity, H. pylori infection, or both.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Olga Sokolova, Michael Naumann
Summary: Gastric cancer is a major cause of cancer-related deaths globally, and its development is influenced by genetic predisposition, environmental factors, and Helicobacter pylori infection. Matrix metalloproteinases (MMPs) play an active role in the progression of gastric cancer, with bacterial dependence being less significant in later stages.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Hee Kyong Na, Sung Hyun Won, Ji Yong Ahn, Kim Ga Hee, Kee Wook Jung, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung, Hwa Jung Kim
Summary: Duodenal MALT lymphoma is very rare, and treatment outcomes seem to be inferior to those of gastric MALT lymphoma. The study findings showed lower rates of H. pylori infection and lymph node metastasis in patients with duodenal MALT lymphoma compared to gastric MALT lymphoma, as well as lower complete remission rates. Complications such as bleeding, stricture, and transformation to high-grade lymphoma were also more common in duodenal MALT lymphoma patients than in gastric MALT lymphoma patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Editorial Material
Microbiology
Agustina Taglialegna
Summary: In this study, Sharafutdinov et al. report the identification of a single nucleotide polymorphism in the gene encoding the HtrA protease of Helicobacter pylori that is linked to gastric cancer.
NATURE REVIEWS MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
G. Van de Vyver, T. Vandamme, P. H. Steger, D. Staessen
Summary: This case report describes two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma, with one patient successfully treated with Helicobacter Pylori eradication therapy, and the other achieving complete remission with localized radiotherapy after initial misdiagnosis of cocaine-induced ulcerations. More aggressive treatment modalities may be necessary in the absence of Helicobacter Pylori.
ACTA GASTRO-ENTEROLOGICA BELGICA
(2021)
Article
Multidisciplinary Sciences
Tomohiko Yasuda, Hyun Seok Lee, Su Youn Nam, Hiroto Katoh, Yuko Ishibashi, Somay Yamagata Murayama, Hidenori Matsui, Hiroki Masuda, Emiko Rimbara, Nobuyuki Sakurazawa, Hideyuki Suzuki, Hiroshi Yoshida, Yasuyuki Seto, Shumpei Ishikawa, Seong Woo Jeon, Masahiko Nakamura, Sachiyo Nomura
Summary: Genetic analysis and culturing techniques for gastric non-Helicobacter pylori Helicobacter (NHPH) are advancing, with NHPH reported to accompany certain gastric conditions. A study on Korean gastric cancer patients found a low percentage positive for NHPH, suggesting it may play a role in gastric cancer development, albeit with lower pathogenicity compared to H. pylori.
SCIENTIFIC REPORTS
(2022)
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Jose Garcia, Maria Chaparro
Summary: For patients with steroid-refractory ASUC, both standard treatment (cyclosporine and infliximab) and newly developed agents (such as vedolizumab and ustekinumab) are effective options.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: Infants exposed to biological drugs in utero have adequate serological responses to vaccines, and there are no relevant adverse events for non-live inactivated vaccines. Live-attenuated vaccines should be avoided in children with detectable levels of biological drugs. Breastfeeding by mothers treated with biologics is considered safe for infants, and the benefits of breastfeeding while receiving treatment and adhering to infant immunization programs outweigh any potential risk.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Maria Jose Casanova, Oscar Nantes, Pilar Varela, Milagros Vela-Gonzalez, Montserrat Rivero, Olivia Sierra-Gabarda, Sabino Riestra, Manuel Barreiro-de Acosta, Maria del Mar Martin-Rodriguez, Carla Jerusalen Gargallo-Puyuelo, Cristina Reygosa, Roser Munoz, Irene Garcia de la Filia-Molina, Andrea Nunez-Ortiz, Lilyan Kolle, Margalida Calafat, Jose Maria Huguet, Eva Iglesias-Flores, Teresa de Jesus Martinez-Perez, Orencio Bosch, Jose Maria Duque-Alcorta, Santiago Frago-Larramona, Manuel Van Domselaar, Victor Manuel Gonzalez-Cosano, Luis Bujanda, Saioa Rubio, Alejo Mancebo, Beatriz Castro, Santiago Garcia-Lopez, Ruth de Francisco, Laura Nieto-Garcia, Viviana Laredo, Ana Gutierrez-Casbas, Francisco Mesonero, Eduardo Leo-Carnerero, Fiorella Canete, Lucia Ruiz, Beatriz Gros, Maria del Moral-Martinez, Cristina Rodriguez, Maria Chaparro, Javier P. Gisbert
Summary: This study compared the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained the adalimumab originator versus those who switched to adalimumab biosimilar. The results showed that switching to adalimumab biosimilar did not show any significant differences in treatment persistence, clinical efficacy, and safety outcomes compared to maintaining the originator.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F. Liau, Javier P. Gisbert
Summary: This study investigated the use of CT-P13 in the treatment of patients with Crohn's disease and ulcerative colitis. The results showed that the safety information for CT-P13 was consistent with the known safety profile for IFX and did not alter the established benefit-risk profile of CT-P13.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm
Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Javier P. Gisbert, Maria Chaparro
Summary: Surgery is not a cure for Crohn's disease, and postoperative recurrence is common. This article critically reviews the role of anti-TNF agents and new biologics in preventing and treating postoperative recurrence in Crohn's disease. Anti-TNFs have been shown to be the most effective agents in preventing and treating postoperative recurrence, while the effectiveness of vedolizumab and ustekinumab is still unclear.
Article
Gastroenterology & Hepatology
Angeles Perez-Aisa, Olga P. Nyssen, Alma Keco-Huerga, Luis Rodrigo, Alfredo J. Lucendo, Blas J. Gomez-Rodriguez, Juan Ortuno, Monica Perona, Jose Maria Huguet, Oscar Nunez, Luis Fernandez-Bermejo, Jesus Barrio, Angel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernandez-Bermej, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela, Ana Campillo, Luisa de la Pena-Negro, Manuel Dominguez Cajal, Luis Bujanda, Diego Burgos-Santamaria, Fernando Bermejo, Victor Gonzalez-Carrera, Ramon Pajares, Pedro Almela Notari, Javier Tejedor-Tejada, Montserrat Planella, Itxaso Jimenez, Yolanda Arguedas Lazaro, Antonio Cuadrado-Lavin, Isabel Perez-Martinez, Edurne Amorena, Jesus M. Gonzalez-Santiago, Teresa Angueira, Virginia Flores, Samuel J. Martinez-Dominguez, Manuel Pabon-Carrasco, Benito Velayos, Alicia Algaba, Consuelo Ramirez, Enrique Alfaro Almajano, Manuel Castro-Fernandez, Noelia Alcaide, Patricia Sanz Segura, Anna Cano-Catala, Natalia Garcia-Morales, Leticia Moreira, Francis Megraud, Colm O'Morain, Xavier Calvet, Javier P. Gisbert
Summary: This study analyzed the effectiveness and safety of triple-dose administration of single capsule bismuth quadruple therapy (scBQT) in patients included in the European Registry on Helicobacter pylori Management. The results showed that the three times a day treatment schedule was more effective than the traditional four times a day schedule in terms of overall cure rates. There were no differences observed in treatment adherence or safety between the two regimens.
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, M. Azkargorta, I. Lloro, I. Soleto Fernandez, M. Orejudo, C. Ramirez, S. Garcia, J. Mercado, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, I. Lloro, M. Azkargorta, C. Ramirez, I. Soleto Fernandez, M. Orejudo, S. Garcia, J. Mercado, C. H. Gordillo, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, F. Mesonero, R. de Francisco, F. Canete, J. M. Benitez, B. Sicilia, M. D. Martin Arranz, L. de Castro, A. Y. Carbajo, A. Gutierrez, M. Calvo, M. J. Casanova, C. Gonzalez-Munoza, M. Miguel, E. Alfambra, M. Rivero, A. J. Lucendo, C. A. Tardillo, P. Almela, L. Bujanda, M. Van Domselaar, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, M. Piqueras, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado, B. Antolin, P. Ramirez de la Piscina, F. Bermejo, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, M. Chaparro, J. M. Benitez, M. D. Martin Arranz, R. de Francisco, M. Piqueras, L. de Castro, A. Y. Carbajo, F. Bermejo, M. Minguez, A. Gutierrez, F. Mesonero, F. Canete, C. Gonzalez-Munoza, M. Calvo, B. Sicilia, E. Alfambra, C. A. Tardillo, M. Rivero, A. J. Lucendo, L. Bujanda, M. Van Domselaar, P. Almela, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado-Guillena, B. Antolin, P. Ramirez de la Piscina, M. J. Casanova, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
A. B. Julian, D. Casas-Deza, R. Vicente-Lidon, B. Beltran, E. Domenech, A. Gutierrez-Casbas, M. Manosa, Y. Zabana, E. Caudevilla-Biota, P. Corsino-Roche, E. Sierra-Moros, L. E. Franco-Fobe, S. Pina-Echevarria, E. Garcia-Gonzalez, E. Alfambra, C. Gargallo-Pueyo, B. Sicilia, L. Arias, M. J. Alcala-Escriche, L. Madero-Velazquez, R. Ferreiro-Iglesias, A. Palmero-Perez, M. Calafat, S. Rubio-Iturria, I. Moraleja-Yudego, Y. Ber-Nieto, S. Garcia-Mateo, J. P. Gisbert, M. Barreiro-de Acosta, S. Garcia-Lopez
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, L. Bujanda, M. Manosa, I. Perez-Martinez, M. J. Casanova, L. de la Pena, M. de Benito, M. Rivero, P. Varela, L. Bernal, A. C. Franco, Y. Ber, M. Piqueras, C. Tardillo, A. Ponferrada, S. Olivares, A. J. Lucendo, P. Gilabert, M. Sierra Ausin, M. Bellart, A. Herrarte, M. Calafat, R. de Francisco, J. P. Gisbert, J. Guardiola, E. Domenech, F. Bermejo
JOURNAL OF CROHNS & COLITIS
(2023)